MergerLinks Header Logo

Submit Deal

Submit Deal

Cover Image INTERCEPT PHARMACEUTICALS
INTERCEPT PHARMACEUTICALS

INTERCEPT PHARMACEUTICALS

Summary

Intercept Pharmaceuticals is an American biopharmaceutical company incorporated in 2002, focusing on the development of novel synthetic bile acid analogs to treat chronic liver diseases.

Deals Overview

Total Deals2
Valued Deals2
Total Value£ 1.01 B
Avg. Deal Size£ 504 M

Market Context

Sort

mb

michael blash

Senior Vice President, Corporate Affairs at INTERCEPT PHARMACEUTICALS

Manager

1

Deal

£ 649 M

Total Value

jd

jerome durso

President and CEO at INTERCEPT PHARMACEUTICALS

Manager

2

Deals

£ 1.01 B

Total Value

ns

nareg sagherian

Executive Director, Global Investor Relations at INTERCEPT PHARMACEUTICALS

Manager

1

Deal

£ 649 M

Total Value

By continuing, you agree to our Terms & Conditions and our Data Privacy Policy

Privacy PolicyTerms of ServiceContact UsCookie Preferences

All rights reserved. Copyright © 2025 Datasite